Regeneron Pharmaceuticals, Inc.REGNNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank43
3Y CAGR-10.7%
5Y CAGR+0.4%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-10.7%/yr
vs +31.1%/yr prior
5Y CAGR
+0.4%/yr
Recent deceleration
Acceleration
-41.8pp
Decelerating
Percentile
P43
Within normal range
vs 5Y Ago
1x
Modest growth
Streak
1 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 11.79% |
| 2024 | 31.26% |
| 2023 | 30.45% |
| 2022 | 16.56% |
| 2021 | 4.91% |
| 2020 | 11.58% |
| 2019 | 9.90% |
| 2018 | 5.61% |
| 2017 | -0.92% |
| 2016 | 26.00% |